Stoke Therapeutics Inc (STOK) - News Archive

Stoke Therapeutics, Inc., a Nasdaq-listed biotechnology innovator, continues to make significant strides in RNA medicine with its lead investigational therapy, zorevunersen, aimed at modifying diseases such as Dravet sy...

Stoke Therapeutics Showcases Groundbreaking Approach to RNA Medicine at 24th Annual Needham Virtual Healthcare Conference In an exciting development for the field of biotechnology, Stoke Therapeutics, Inc. (Nasdaq: STOK...

Stoke Therapeutics, Inc. (Nasdaq: STOK), based in Bedford, Massachusetts, is making noteworthy strides in the biotechnology sector with its pioneering approach to RNA medicine. Focused on restoring protein expression, S...

Stoke Therapeutics, Inc. a pioneering biotechnology company listed on Nasdaq under the symbol STOK, continues to make significant strides in the battle against Dravet syndrome a severe and often debilitating form of epi...

The landscape of pharmaceutical innovation is continually evolving, especially for complex neurological disorders like Dravet Syndrome. At the forefront of this battle is Stoke Therapeutics, Inc. (Nasdaq: STOK), a compa...

: Stoke Therapeutics Inc. has recently released its financial results for the third quarter, providing insights into its business operations and strategic outlook moving forward. While the company is currently facing ch...

Zorevunersen: A Beacon of Hope for Dravet Syndrome Patients In recent highlights from the 15th European Epilepsy Congress (EEC), Stoke Therapeutics, Inc. (NASDAQ: STOK) unveiled compelling data regarding zorevunersen (S...

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company focused on addressing severe diseases through RNA-based therapies, is set to present promising clinical data on its leading candidate, zorevunersen (STK-0...

Stoke Therapeutics, Inc., a Bedford, Massachusetts-based biotechnology firm, is making significant strides in the burgeoning field of RNA-based medicines, aimed at treating severe genetic diseases. The company recently...

BEDFORD, Mass. - Stoke Therapeutics, a prominent biotechnology company engaged in developing RNA-based medicines to tackle severe diseases, has recently announced that its management will be presenting at two major inve...

Stoke Therapeutics, a renowned biotechnology company focused on developing innovative RNA-based medicines to address the root causes of severe diseases, has recently announced its participation in two upcoming prestigio...

Stoke Therapeutics Appoints Thomas Leggett as Chief Financial OfficerBedford, MA Stoke Therapeutics, Inc. (Nasdaq: STOK), a prominent biotechnology company focusing on developing RNA-based medicines to tackle the root c...